Back

Diabetes may modify the efficacy of primary prevention implantable cardioverter-defibrillators in non-ischemic systolic heart failure: an extended follow-up of the DANISH trial

26 August 2022 (10:15 - 11:00)
Organised by:
Congress Presentation Part of: Chronic heart failure and diabetes Implantable Cardioverter-Defibrillator (ICD) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Seiko N Doi

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
Biomarker profiles and pathophysiological pathways in patients with chronic heart failure and metabolic syndrome
Miss C. van der Hoef (Groningen, NL)
Abstract Slides
Presentation thumbnail
Timing of initiation of sodium-glucose co-transporter 2 inhibitor in patients with diabetes and chronic cardiac failure
Doctor W. Sun (Shatin, HK)
Abstract Slides
Presentation thumbnail
Prediabetes relates to impaired mitochondrial function in human ventricular myocardium
Mr E. Zweck (Duesseldorf, DE)
Abstract Slides
Presentation thumbnail
Outcomes in hospitalised diabetic ketoacidosis patients with underlying heart failure: a national inpatient sample analysis
Doctor S. Yalamanchili (Greenville, US)
Abstract Slides
Presentation thumbnail
Risk of heart failure following short-term non-steroidal anti-inflammatory drug use in patients with type 2 diabetes mellitus
Mr J. Strange (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure and diabetes

The Event

Event poster

ESC Congress 2022

26 August 2022 10:15 CET
You may be interested in
thumbnail
Congress Session
Debate on primary prevention in ICD therapy
thumbnail
Congress Session
Arrhythmias and devices
thumbnail
Congress Session
When to consider device therapy in HFrEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources